SG11201806639VA - New streptococcal proteases - Google Patents
New streptococcal proteasesInfo
- Publication number
- SG11201806639VA SG11201806639VA SG11201806639VA SG11201806639VA SG11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA SG 11201806639V A SG11201806639V A SG 11201806639VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- proteases
- igg
- methods
- Prior art date
Links
- 102000035195 Peptidases Human genes 0.000 title abstract 4
- 108091005804 Peptidases Proteins 0.000 title abstract 4
- 239000004365 Protease Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/641—Cysteine endopeptidases (3.4.22)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1630021 | 2016-02-04 | ||
| PCT/EP2017/052463 WO2017134274A1 (en) | 2016-02-04 | 2017-02-03 | New streptococcal proteases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806639VA true SG11201806639VA (en) | 2018-09-27 |
Family
ID=57995190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806639VA SG11201806639VA (en) | 2016-02-04 | 2017-02-03 | New streptococcal proteases |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12006530B2 (enExample) |
| EP (1) | EP3411389B1 (enExample) |
| JP (2) | JP7123801B2 (enExample) |
| KR (1) | KR102704583B1 (enExample) |
| CN (1) | CN109311951B (enExample) |
| AU (1) | AU2017214441B2 (enExample) |
| CA (1) | CA3013527C (enExample) |
| DK (1) | DK3411389T3 (enExample) |
| ES (1) | ES2877754T3 (enExample) |
| PL (1) | PL3411389T3 (enExample) |
| PT (1) | PT3411389T (enExample) |
| SG (1) | SG11201806639VA (enExample) |
| WO (1) | WO2017134274A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2944767C (en) | 2014-04-04 | 2022-07-12 | Mayo Foundation For Medical Education And Research | Isotyping immunoglobulins using accurate molecular mass |
| US11209439B2 (en) | 2015-09-24 | 2021-12-28 | Mayo Foundation For Medical Education And Research | Identification of immunoglobulin free light chains by mass spectrometry |
| JP7123801B2 (ja) | 2016-02-04 | 2022-08-23 | ジェノビス エービー | 新しい連鎖球菌プロテアーゼ |
| US10955420B2 (en) | 2016-09-07 | 2021-03-23 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| CN111183221B (zh) | 2017-05-26 | 2024-04-09 | 杰诺维斯公司 | 用于o-糖蛋白的蛋白酶和结合多肽 |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| WO2019055632A1 (en) | 2017-09-13 | 2019-03-21 | Mayo Foundation For Medical Education And Research | IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN CHAINS J |
| EP3681528B1 (en) | 2017-09-13 | 2025-07-23 | Mayo Foundation for Medical Education and Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| CN111447946A (zh) * | 2017-12-15 | 2020-07-24 | 英特维特国际股份有限公司 | 用于针对猪链球菌进行保护的疫苗 |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| BR112022015921A2 (pt) | 2020-02-14 | 2022-10-04 | Ultragenyx Pharmaceutical Inc | Terapia gênica para tratar o transtorno de deficiência de cdkl5 |
| GB202002072D0 (en) * | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| JP2023532219A (ja) * | 2020-06-18 | 2023-07-27 | 上海宝済薬業有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの突然変異体 |
| IL301955A (en) | 2020-10-07 | 2023-06-01 | Asklepios Biopharmaceutical Inc | Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21 |
| CA3216491A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| US20240271115A1 (en) * | 2021-06-15 | 2024-08-15 | The University Of North Carolina At Chapel Hill | Methods and compositions for depleting antibodies |
| WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| CN118265540A (zh) * | 2021-11-18 | 2024-06-28 | 英特维特国际股份有限公司 | 产生针对猪链球菌的疫苗的方法以及所述疫苗 |
| TW202436348A (zh) * | 2022-11-25 | 2024-09-16 | 日商中外製藥股份有限公司 | 蛋白質的製造方法 |
| WO2025047641A1 (ja) * | 2023-08-25 | 2025-03-06 | 積水メディカル株式会社 | 免疫学的測定方法、免疫学的測定用試薬、免疫学的測定用検体前処理液、及び免疫学的測定用試薬キット、非特異反応抑制剤 |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2824074A1 (fr) * | 2001-04-26 | 2002-10-31 | Pasteur Institut | Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| WO2006069200A2 (en) | 2004-12-22 | 2006-06-29 | Novartis Vaccines And Diagnostics Inc. | Group b streptococcus |
| PT1901773E (pt) * | 2005-06-09 | 2012-06-06 | Hansa Medical Ab | Utilização da proteinase ides (de s. pyogenes) para o tratamento de doenças e rejeição de enxertos |
| EP2190984B1 (en) | 2007-09-14 | 2013-09-04 | Genovis Ab | Methods and kits for purification and detection of glycosylated IgG |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201316744D0 (en) * | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| JP7123801B2 (ja) | 2016-02-04 | 2022-08-23 | ジェノビス エービー | 新しい連鎖球菌プロテアーゼ |
-
2017
- 2017-02-03 JP JP2018540841A patent/JP7123801B2/ja active Active
- 2017-02-03 ES ES17703958T patent/ES2877754T3/es active Active
- 2017-02-03 AU AU2017214441A patent/AU2017214441B2/en active Active
- 2017-02-03 CN CN201780022485.6A patent/CN109311951B/zh active Active
- 2017-02-03 SG SG11201806639VA patent/SG11201806639VA/en unknown
- 2017-02-03 PT PT177039583T patent/PT3411389T/pt unknown
- 2017-02-03 DK DK17703958.3T patent/DK3411389T3/da active
- 2017-02-03 PL PL17703958T patent/PL3411389T3/pl unknown
- 2017-02-03 WO PCT/EP2017/052463 patent/WO2017134274A1/en not_active Ceased
- 2017-02-03 EP EP17703958.3A patent/EP3411389B1/en active Active
- 2017-02-03 US US16/075,059 patent/US12006530B2/en active Active
- 2017-02-03 CA CA3013527A patent/CA3013527C/en active Active
- 2017-02-03 KR KR1020187025476A patent/KR102704583B1/ko active Active
-
2022
- 2022-03-30 JP JP2022056522A patent/JP2022115853A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3411389A1 (en) | 2018-12-12 |
| CA3013527A1 (en) | 2017-08-10 |
| KR20180124857A (ko) | 2018-11-21 |
| JP2019506866A (ja) | 2019-03-14 |
| AU2017214441B2 (en) | 2021-08-19 |
| KR102704583B1 (ko) | 2024-09-06 |
| US20190345533A1 (en) | 2019-11-14 |
| PT3411389T (pt) | 2021-06-28 |
| EP3411389B1 (en) | 2021-03-24 |
| ES2877754T3 (es) | 2021-11-17 |
| JP2022115853A (ja) | 2022-08-09 |
| JP7123801B2 (ja) | 2022-08-23 |
| PL3411389T3 (pl) | 2021-10-25 |
| AU2017214441A1 (en) | 2018-08-16 |
| CA3013527C (en) | 2023-09-05 |
| DK3411389T3 (da) | 2021-06-21 |
| CN109311951B (zh) | 2022-10-11 |
| CN109311951A (zh) | 2019-02-05 |
| WO2017134274A1 (en) | 2017-08-10 |
| US12006530B2 (en) | 2024-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806639VA (en) | New streptococcal proteases | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201811405QA (en) | Improved differentiation method | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201810179RA (en) | Novel crispr enzymes and systems | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201811169WA (en) | Methods and systems for recommending to a first user media assets for inclusion in a playlist for a second user based on the second user's viewing activity | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |